Linagliptin: Effectiveness for glycemic control, safety, and cardiovascular risk factors in patients with type 2 diabetes

Linagliptin: Effectiveness for glycemic control, safety, and cardiovascular risk factors in patients with type 2 diabetes

Sara Arellano-Montaño 1, Valentín Sánchez-Pedraza 2, Jorge Yamamoto-Cuevas 3, Sonia Citlali Juarez-Comboni 4

1 Department of Endocrinology, Hospital General de México, Mexico City, Mexico; 2 Servicio de Endocrinología, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México, México; 3 General Hospital of Mexico, Mexico City, Mexico; 4 Salvador Zubirán National Institute of Health Sciences and Nutrition INCMNSZ, Mexico City, Mexico

Sara Arellano-Montaño, Valentín Sánchez-Pedraza, Jorge Yamamoto-Cuevas, Sonia Citlali Juarez-Comboni

La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.

*Correspondence: Jorge Yamamoto-Cuevas, Email not available

Summary

Keywords:  Atherosclerosis. Diabetes complications. DPP-4i. Linagliptin. Metformin. Cardiovascular risk. Sulfonylurea.

Contents

DOI not available
Add to Mendeley
    Descargar PDF
    English versión
    DOI not available